US Bancorp DE decreased its position in Smith & Nephew plc (NYSE:SNN – Free Report) by 6.7% in the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 28,842 shares of the medical equipment provider’s stock after selling 2,056 shares during the period. US Bancorp DE’s holdings in Smith & Nephew were worth $930,000 at the end of the most recent quarter.
Other large investors have also recently modified their holdings of the company. Bessemer Group Inc. boosted its holdings in shares of Smith & Nephew by 397.3% in the fourth quarter. Bessemer Group Inc. now owns 920 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 735 shares during the period. Clear Street Markets LLC bought a new position in Smith & Nephew in the fourth quarter worth approximately $38,000. Grove Bank & Trust raised its stake in Smith & Nephew by 19.3% in the second quarter. Grove Bank & Trust now owns 2,109 shares of the medical equipment provider’s stock worth $68,000 after buying an additional 341 shares in the last quarter. Zions Bancorporation N.A. raised its stake in Smith & Nephew by 44.6% in the first quarter. Zions Bancorporation N.A. now owns 3,337 shares of the medical equipment provider’s stock worth $106,000 after buying an additional 1,029 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in Smith & Nephew by 138.2% in the first quarter. Tower Research Capital LLC TRC now owns 4,566 shares of the medical equipment provider’s stock worth $127,000 after buying an additional 2,649 shares in the last quarter. Hedge funds and other institutional investors own 8.65% of the company’s stock.
Smith & Nephew Stock Up 0.5 %
NYSE SNN opened at $25.81 on Monday. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.19 and a quick ratio of 0.83. The stock’s fifty day moving average price is $24.06 and its 200 day moving average price is $27.65. Smith & Nephew plc has a 1 year low of $21.52 and a 1 year high of $33.08.
Wall Street Analysts Forecast Growth
A number of equities analysts recently commented on SNN shares. Stifel Nicolaus started coverage on shares of Smith & Nephew in a research note on Friday, October 13th. They issued a “hold” rating for the company. HSBC raised shares of Smith & Nephew from a “hold” rating to a “buy” rating in a research note on Tuesday, October 31st. StockNews.com downgraded Smith & Nephew from a “strong-buy” rating to a “buy” rating in a research report on Monday, October 2nd. JPMorgan Chase & Co. raised Smith & Nephew from a “neutral” rating to an “overweight” rating in a research report on Friday, November 3rd. Finally, UBS Group raised Smith & Nephew from a “sell” rating to a “neutral” rating in a research report on Tuesday, August 8th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, Smith & Nephew has an average rating of “Moderate Buy” and an average target price of $1,240.00.
Check Out Our Latest Stock Analysis on SNN
Smith & Nephew Profile
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. The company operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures.
Further Reading
Receive News & Ratings for Smith & Nephew Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Smith & Nephew and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: defenseworld.net
